What we do
One platform. Many new imaging agents.
Today's imaging agents are either easy to make but short-lived, or precise but hard to make without damaging the molecule. We remove that tradeoff.
Seeing what is hard to see today
Opens the way to precise imaging of cancers and other diseases that are difficult to detect with current agents.
Gentle on delicate molecules
Keeps the targeting molecule intact, so it still finds what it was designed to find.
Fits existing facilities
Designed to work with the equipment imaging centres already use.
Pipeline of new imaging agents, with lead programmes progressing toward first-in-human studies.